Streamlined European Pathway Needed For Biosimilars To Hit Smaller Targets

Development Costs Are Currently Too High For Smaller-Value Biologics To Be Viable

A more streamlined European regulatory pathway for biosimilars – potentially removing the requirement for confirmatory efficacy trials – is needed for the industry to be able to feasibly offer competition to smaller-value biologic brands, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference.

Medicines for Europe 18th biosimilars conference
Adrian van den Hoven, Esa Heinonen and Isabell Remus (from center to right) discussed the need for a streamlined European pathway for biosimilars • Source: Medicines for Europe

A more streamlined European regulatory pathway for biosimilars, eliminating the requirement for confirmatory Phase III efficacy trials, is needed for smaller-value biologic brands to become viable targets for biosimilar competition, according to European biosimilar industry leaders.

Speaking at European off-patent industry association Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels, Belgium, in early October, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

BC Partners Bids For Biogaran Buyout – But Will It Face French Pushback?

 
• By 

Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?

Roche Braces For Late 2026 Biosimilar Wave

 
• By 

Roche expects biosimilars to Perjeta and Xolair by the end of 2026, marking a key inflection point for two of its major franchises. Shanghai Henlius Biotech leads development for pertuzumab, while Celltrion is positioned as the frontrunner for omalizumab.

Sandoz Strikes $300m Deal With Just-Evotec For French Biosimilars Site

 
• By 

Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.

Generics Bulletin’s Top 50 Ranking For 2025

 
• By 

This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

More from Products

The Generics Bulletin Top 50, Part Three: New Firms Enter Global Grouping

 
• By 

In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.

Latest EMA Biosimilar Nods Come For Henlius, Alteogen And Biocon

 
• By 

Denosumab, aflibercept and ustekinumab biosimilars received positive opinions from the EMA’s CHMP at its meeting in July, along with an Opsumit generic from Accord.

The Generics Bulletin Top 50, Part Two: Leading Players Leapfrog The Competition

 
• By 

In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.